Author: Caracciolo, Massimo; Macheda, Sebastiano; Labate, Demetrio; Tescione, Marco; La Scala, Stefano; Vadalà , Eugenio; Squillaci, Rosalba; D’Aleo, Francesco; Morabito, Antonella; Garreffa, Cristina; Marciano, Maria Concetta; Oliva, Esther N.
Title: Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome Cord-id: 06i2nv0t Document date: 2020_8_25
ID: 06i2nv0t
Snippet: Severe cases of COVID-19 present with serious lung inflammation, acute respiratory distress syndrome and multiorgan damage. SARS-CoV-2 infection is associated with high cytokine levels, including interleukin-6 and certain subsets of immune cells, in particular, NK, distinguished according to the cell surface density of CD56. Cytokine levels are inversely correlated with lymphocyte count, therefore cytokine release syndrome may be an impediment to the adaptive immune response against SARS-CoV-2 i
Document: Severe cases of COVID-19 present with serious lung inflammation, acute respiratory distress syndrome and multiorgan damage. SARS-CoV-2 infection is associated with high cytokine levels, including interleukin-6 and certain subsets of immune cells, in particular, NK, distinguished according to the cell surface density of CD56. Cytokine levels are inversely correlated with lymphocyte count, therefore cytokine release syndrome may be an impediment to the adaptive immune response against SARS-CoV-2 infection. Canakinumab, a monoclonal antibody targeting IL-1β is under investigation for the treatment of severe SAR-CoV-2 infection. An 85 year old male presenting in our hospital with COVID-19, whose condition was complicated by acute respiratory distress syndrome and cardiac and renal failure (with oliguria) after 25 days of hospitalization, was intubated and received canakinumab for compassionate use. On the next day, diuresis recovered and conditions improved: high IL-6 levels and NK cells expressing CD56(bright) (associated with cytokine relase) were significantly reduced giving rise to NK CD56(dim). Patient died on day 58 with pulmonary bacterial superinfection and persistent SARS-CoV-2 positivity. In conclusion, canakinumab rescued a high risk, very elderly patient, from multiorgan damage complicating COVID-19. It may represent an useful treatment in severe cases.
Search related documents:
Co phrase search for related documents- activation inflammatory cytokine and adaptive immune response: 1
- activation inflammatory cytokine and lung injury: 1, 2
- active involvement and acute ards respiratory distress syndrome: 1
- active involvement and lopinavir ritonavir: 1
- active involvement and lung tissue: 1
- acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and liver renal: 1, 2, 3, 4, 5, 6, 7, 8
- acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lung pattern: 1, 2, 3, 4, 5, 6, 7, 8
- acute ards respiratory distress syndrome and lung proinflammatory cytokine: 1
- acute ards respiratory distress syndrome and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adaptive immune response and liver renal: 1
- adaptive immune response and lopinavir ritonavir: 1
- adaptive immune response and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9
- adaptive immune response and lung tissue: 1, 2, 3, 4, 5, 6, 7
- liver renal and lopinavir ritonavir: 1, 2, 3, 4, 5
- liver renal and lung injury: 1
- liver renal and lung pattern: 1, 2
Co phrase search for related documents, hyperlinks ordered by date